Seelos Therapeutics, Inc. Total Liabilities
Seelos Therapeutics, Inc. total liabilities. Based on the latest financial reports, Seelos Therapeutics, Inc. (SEELQ) has total liabilities worth $30.51 Million USD as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Seelos Therapeutics, Inc. to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Seelos Therapeutics, Inc. (2020–2023)
Total liabilities of Seelos Therapeutics, Inc. from 2020 to 2023. This chart illustrates how Seelos Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Seelos Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Seelos Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Innoviz Technologies Ltd
NASDAQ:INVZW
|
USA | $61.40 Million |
|
RPCG PCL F
F:R4Q
|
Germany | €5.06 Billion |
|
Jack Nathan Medical Corp
V:JNH
|
Canada | CA$16.75 Million |
|
Nuvve Holding Corp
NASDAQ:NVVEW
|
USA | $18.67 Million |
|
Godha Cabcon & Insulation Limited
NSE:GODHA
|
India | Rs-994.82 Million |
|
Solartron Public Company Limited
F:TUUF
|
Germany | €868.24 Million |
|
Advantage Solutions Inc
NASDAQ:ADVWW
|
USA | $2.29 Billion |
|
Katapult Holdings Equity Warrants Exp 09 June 2026
NASDAQ:KPLTW
|
USA | $108.02 Million |
Liability Composition Analysis (2020–2023)
This chart breaks down Seelos Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Seelos Therapeutics, Inc. total assets.
Liquidity & Leverage Metrics
Seelos Therapeutics, Inc. Total Liabilities Ratios Explained
Seelos Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 12.82 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Seelos Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Seelos Therapeutics, Inc. (2020–2023)
The table below shows the annual total liabilities of Seelos Therapeutics, Inc. from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $38.93 Million | +16.70% |
| 2022-12-31 | $33.36 Million | +27.43% |
| 2021-12-31 | $26.18 Million | +75.43% |
| 2020-12-31 | $14.92 Million | -- |
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more